San Francisco Sentry Investment Group CA Purchases New Stake in Eli Lilly and Company (LLY)

San Francisco Sentry Investment Group CA bought a new position in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,576 shares of the company’s stock, valued at approximately $129,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of The Ozarks increased its stake in shares of Eli Lilly and by 24.9% in the first quarter. Bank of The Ozarks now owns 8,723 shares of the company’s stock valued at $734,000 after purchasing an additional 1,740 shares during the period. Stifel Financial Corp increased its stake in shares of Eli Lilly and by 2.6% in the first quarter. Stifel Financial Corp now owns 709,703 shares of the company’s stock valued at $59,657,000 after purchasing an additional 17,892 shares during the period. ARS Investment Partners LLC increased its stake in shares of Eli Lilly and by 7.3% in the first quarter. ARS Investment Partners LLC now owns 2,950 shares of the company’s stock valued at $248,000 after purchasing an additional 200 shares during the period. Wayne Hummer Investments L.L.C. increased its stake in shares of Eli Lilly and by 105.4% in the first quarter. Wayne Hummer Investments L.L.C. now owns 6,775 shares of the company’s stock valued at $570,000 after purchasing an additional 3,477 shares during the period. Finally, Spinnaker Trust acquired a new stake in shares of Eli Lilly and in the first quarter valued at approximately $226,000. 76.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “San Francisco Sentry Investment Group CA Purchases New Stake in Eli Lilly and Company (LLY)” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3050903/san-francisco-sentry-investment-group-ca-purchases-new-stake-in-eli-lilly-and-company-lly.html.

A number of research firms recently commented on LLY. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Leerink Swann raised their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $89.97.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 772,003 shares of company stock worth $64,837,441. 0.20% of the stock is owned by company insiders.

Eli Lilly and Company (LLY) opened at $83.68 on Thursday. The company has a market cap of $91,919.42, a price-to-earnings ratio of 20.41, a P/E/G ratio of 1.84 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $64.18 and a twelve month high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the firm posted $0.88 EPS. The business’s revenue was up 9.0% compared to the same quarter last year. analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.